Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.33), $0.39 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $160 million versus the consensus estimate of $145.75 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2022 revenue of $575 million, versus the consensus of $595 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.